HC Wainwright Issues Negative Forecast for Indivior Earnings

Indivior PLC (NASDAQ:INDV) – Investment analysts at HC Wainwright lowered their Q1 2026 earnings estimates for shares of Indivior in a research report issued on Friday, February 27th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.67 for the quarter, down from their previous estimate of $0.72. HC Wainwright has a “Buy” rating and a $48.00 price target on the stock. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior’s Q4 2026 earnings at $0.84 EPS and FY2030 earnings at $3.78 EPS.

A number of other equities analysts have also recently commented on INDV. Northland Securities set a $50.00 price objective on shares of Indivior in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research note on Wednesday, January 28th. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Indivior has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Indivior Trading Down 2.9%

INDV stock opened at $32.72 on Monday. Indivior has a 1-year low of $8.34 and a 1-year high of $38.00. The business’s 50 day simple moving average is $34.55 and its 200 day simple moving average is $30.09. The firm has a market capitalization of $4.09 billion, a PE ratio of 19.95 and a beta of 0.83.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The firm had revenue of $358.00 million for the quarter, compared to analyst estimates of $305.62 million.

Insiders Place Their Bets

In other news, Director Daniel A. Ninivaggi bought 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director directly owned 16,923 shares in the company, valued at $598,904.97. This represents a 4.80% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barbara Ryan purchased 775 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director owned 1,963 shares in the company, valued at $69,470.57. This trade represents a 65.24% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 4,871 shares of company stock valued at $172,385 over the last 90 days.

Institutional Investors Weigh In On Indivior

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Indivior by 3.4% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock valued at $761,000 after purchasing an additional 700 shares during the last quarter. Blue Trust Inc. grew its position in Indivior by 17.8% in the fourth quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after acquiring an additional 733 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in Indivior during the fourth quarter worth about $30,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Indivior by 544.6% in the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after acquiring an additional 1,013 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.